

# Collin A. Hovinga, PharmD., M.S., FCCP

## EDUCATION

---

<b>Masters of Science in Epidemiology</b> <i>Magna cum laude</i> University of Tennessee Health Science Center, Memphis, TN.	2010
<b>Doctor of Pharmacy</b> , <i>Summa cum laude</i> Creighton University, School of Pharmacy and Allied Health Professions, Omaha, NE.	1997
<b>Bachelor of Science in Biology</b> , <i>Magna cum laude</i> Creighton University, College of Arts and Sciences, Omaha, NE.	1991

## POSTDOCTORAL TRAINING

---

<b>Health Outcomes and Economics Fellowship</b> MD Anderson Cancer Center and University of Texas Southwestern, Houston, TX.	2012-2013
<b>Pediatric Clinical Pharmacology Fellowship</b> Office of Clinical Pharmacology U.S. Food and Drug Administration (FDA), Silver Springs, MD.	2009
<b>Pediatric Pharmacotherapy Fellowship</b> NIH Pediatric Pharmacology Research Unit University of Tennessee, Memphis, TN.	1998- 2000
<b>Pediatric Pharmacotherapy Residency</b> University of Tennessee, Memphis, TN.	1997- 1998

## PROFESSIONAL EXPERIENCE

---

<b>Vice President Rare and Orphan Diseases</b> Critical Path Institute (C-Path)	2022-present
<b>Special Government Employee (SGE)-Advisor</b> Drug Safety and Risk Management, U.S. Food and Drug Administration	2020-present
<b>Senior Vice President, Clinical and Scientific Development</b> The Institute for Advanced Clinical Trials for Children (I-ACT)	2018-2022
<b>Director of Research Support Services</b> Ascension National Hospitals, Ascension Texas and Seton Healthcare Family Austin	2015-2018

<b>Director of Research and Research Integrity</b> Dell Children's Medical Center, Pediatric Surgical Subspecialists	2011-2015
<b>Pediatric Clinical Pharmacologist</b> Department of Neurology and Pediatrics, Dell Children's Medical Center	2011-2015
<b>Special Government Employee (SGE)-Advisor</b> CNS, PNS Division, U.S. Food and Drug Administration	2010-2015
<b>Director of the Neuropharmacology Translational Research Laboratory and Pediatric Clinical Pharmacologist Neurology, PICU/NICU</b> Le Bonheur Children's Medical Center, Division of Clinical Pharmacology	2006-2011
<b>Associate Director of Research and Neuropharmacologist</b> Miami Children's Hospital Research Institute Clinical Neuropharmacologist-Neuroscience	2003-2006
<b>Neuropharmacology Specialist, Research Manager</b> Cleveland Clinic Foundation	2000-2003
<b>Clinical Pharmacologist</b> Le Bonheur Children's Medical Center	1997-1999

#### **ACADEMIC APPOINTMENTS**

---

<b>Clinical Associate Professor of Pharmacy</b> University of Texas at Austin, College of Pharmacy	2011-present
<b>Associate Professor of Pharmacy and Pediatrics</b> University of Tennessee Health Science Center, College of Pharmacy	2011
<b>Assistant Professor of Pharmacy and Pediatrics</b> University of Tennessee Health Science Center, College of Pharmacy	2006-2011
<b>Assistant Professor of Neurosurgery</b> University of Miami School of Medicine, Department of Neurosurgery	2003-2006
<b>Adjunctive Mentor Faculty</b> Creighton University, School of Pharmacy and Allied Health Professions	2001-2005
<b>Assistant Professor</b> Creighton University, College of Arts and Science, Department of Biology	1990-1991

## **WORKING GROUPS, MEMBERSHIPS AND AFFILIATIONS**

---

<b>Collaborative Network for European Clinical Trials for Children (Conect 4 Children)</b>	2018-present
U.S. Representative, International Global Pediatric Interoperability Committee	2018-present
Expert Advisory Committee (WP4)	2018-present
Education and Training Committee (WP6)	2018-present
Vice Chair, External Advisory Committee	2018-present
<b>Enpr-EMA-FDA Working Group on International Collaboration</b>	
U.S. Representative	2018-2022
<b>The International Children's Advisory Network (iCAN)</b>	2017-present
Member, Medical Advisory Board	
Chair, Educational Committee	
<b>Multiregional Clinical Trials (MRCT)</b>	2020-2021
Pediatric Global Research Initiative	
Patient Engagement	
<b>Pfizer, Inc., Groton, CT</b>	2016-2017
Founding Member, Pfizer External Expert Panel (PEEP)	
<b>American College of Clinical Pharmacy</b>	1997-present
Member, 2018 Pediatric Pharmacy Standard Setting Panel	2017-2019
President Elect, Advisory Committee, National Practice Based Research Network	2015
Member, Practice Based Research Committee	2013-2017
Member, Resident/Fellow Core Curriculum Committee	2013-2014
Advisory Committee, National Practice Based Research Network	2012-2018
Secretary Treasurer, Central Nervous System Practice and Research Network	2011-2012
Member, Annual Program Committee 2012	2010-2012
Member, Virtual Committee Advisory Committee	2008-2009
Member, Educational Committee B	2007-2008
Acting Chair, Central Nervous System Practice and Research Network	2006-2007
Chair Elect, Central Nervous System Practice and Research Network	2005-2006
Member, Research Affairs Committee	2002-2006
Member, Industrial Relations Committee	1999-2000
<b>Pediatric Pharmacy Advocacy Group</b>	1997-present
Board Review Faculty-Neurology/Psychiatry	2015-2017
PRN Journal Advisor and Reviewer	1997-present
<b>American Epilepsy Society</b>	2000-2020
Member, Allied Health Professionals	2008-2011
Member, Clinical Therapeutics Committee	2004-2008
Member, Practice Committee	2001-2006

<b>Texas State Autism Spectrum Disorders, Austin, TX</b> Medical Advisory Committee, Planning Committee	2014-2017
<b>U.S. Food and Drug Administration, Silver Springs, MD</b> Special Government Employee, Peripheral and Central Nervous System	2012-2015
<b>Seton Healthcare Family, Austin, TX</b> Member, Institutional Review Board	2012-2015
<b>Children's Optimal Health, Austin, TX</b> Technical Advisory Committee	2012-2017
<b>American Academy of Neurology</b> Member, Pregnancy and Lactation Position Paper Chair, Folate use, lactation/placental transfer, Vitamin K use Co-chair, Pharmacokinetics	2005-2007
<b>American Society of Health-System Pharmacists</b>	1996-2000
<b>Phi Lambda Sigma National Pharmacy Leadership Society</b>	1996-present
<b>Rho Chi National Honor Society</b> Vice President	1995-present 1995-1996

---

## **HONORS AND AWARDS**

Fellow, American College of Clinical Pharmacy	2011
Volunteer Leader Recognition, American Epilepsy Society	2005-2009
Research Sabbatical, American College of Clinical Pharmacy	2001
Dean's Honor Award, Creighton University	1994-1995
Rho Chi Academic Achievement Award	1994
State of Iowa Scholar	1991
Outstanding Chemistry/Biology Student Award	1991
Dean's List Creighton University	1987-1997
Reinhart Condon Academic Scholarship	1987

---

## **CONSULTANCIES AND ADVISORY ACTIVITIES**

### **Patient Advocacy**

<b>Firefly Fund for Niemann-Pick disease type C1 (NPC1)</b> Director, Scientific Advisory Board Healthcare Advisor, Board of Directors	2017-present
<b>Tuberous Sclerosis Alliance</b> Medical and Scientific Advisor	2014-present
<b>HydroAngels</b> Board of Directors / Research Director	2015-2016

<b>Tennessee Epilepsy Foundation</b> Pharmacy and Advocacy	2008-2011
<b>AES/AAN Guidelines for Woman with Epilepsy</b> Lead Pharmacokinetics, Drugs in Lactation, Vitamin Supplementation	2008-2009
<b>Autism Solution Center</b> Board of Directors	2007-2008
<b>Spinal Muscular Atrophy (SMA) Foundation</b>	2005-2007
<b>HiQ Foundation/MRSI, Psychogenics, Inc.</b> Drug Evaluation Consultant	2003-2006
<b>Federal</b>	
<b>NIH-CTSA Standards for Informed Consent</b>	2017
<b>NIH Standard Data Elements for Research</b>	2011-2012
<b>NIH/NINDS Huntington's Study Group –Drug Trials in Disease Modification</b> Translational Research Consultant (CINAPS)	2005-2007
<b>Pharmaceutical</b>	
<b>Questcor Pharmaceuticals</b> Educational Consultant	2008-2010
<b>UCB, Inc.</b> Pharma-Speaker's Bureau	2001-2007
<b>Johnson &amp; Johnson PRD and OrthoMcNeil</b> Consultant Trial Design for Epilepsy	2003-2006
<b>GlaxoSmithKline, Inc.</b> Consultant, Speaker's Bureau	2000-2004
<b>Eisai Pharmaceuticals</b> Consultant	2000-2003
<b>Pfizer</b> Consultant-Pediatric Hypertension Trial Design	1999-2000

## CLINICAL PRACTICE

---

**More than 20 years experiences as a clinical pharmacologist, specializing in pediatrics, neurology, rare diseases, and acute care.**

### **Certification and Licensure**

Pharmacist, State of Tennessee, No. 0000010144, Exp. 7/31/2023	Active
Pharmacist, State of Texas, No. 51309, Exp. 11/30/2023	Active
Immunization Certification, American Pharmaceutical Association	Active
Citi Training Biomedical Research, IRB Member/Chair, GCP	Active

### **Clinical Innovations and Quality Improvement Projects**

Project Mentor, Seton Family Hospitals Quality and Health Outcomes Program, Austin, TX	2013-2018
“Improving Infectious Disease Isolation Practices in General Medicine Floor.”	
“Improving Outcomes and Clinical Workflow in Spasticity Clinic.”	
“Maximization of Concussion Workflow and Patient Related Value.”	
“Factors that Influence Shunt Longevity in Hydrocephalic Patients.”	
“Decrease Waste in Operative Material Use.”	
“Epilepsy Surgical Evaluations-Implementation of a Practice Guideline Based Referral System.”	

## GRANTS

---

### **FDA Grants**

FDA U01F00072201 <b>Advancing Standards and Methodologies to Generate Real World Evidence From Real World Data Through a Neonatal Pilot Project.</b> <u>Co-Investigator.</u>	2020-present
FDA U18FD006297 <b>I-ACT for Children The Development of a Global Pediatric Clinical Trials Network.</b> <u>Co-Principal Investigator.</u>	2017-present

### **NIH Grants – Completed**

NINDS NS065818-01A1 <b>Thrombolysis in Pediatric Stroke (TIPS) grant.</b> <u>Co-Investigator.</u> Study, Director of the Pharmacokinetic Core.	2011-2014
NINDS/HiQ Foundation. <b>Systemic Evaluation of Treatments for Huntington’s Disease,</b> <u>Consultant, Co-Chair.</u> 2004, <u>Chair-</u> 2005-2006.	2004-2006
NINDS NS5045911/NS5045803 <b>Childhood Absence Epilepsy: Rx PK-PD-Pharmacogenetics.</b> <u>Co-Investigator.</u>	2004-2006
NIH/NINDS <b>Committee to Investigate Neuroprotective Studies in Parkinson's</b> (CINPAPS), <u>Consultant</u> (Subcontract), Member Neuropharmacology Advisory Board.	2002-2004

## **Institutional Research Grants**

Inaugural UTHSC Clinical Translational Science Institute K12 Scholar Grant (CTSI) <b>Identification of Genes Modulating Susceptibility with Neonatal Hypoxia-Induced Seizures (HIS).</b>	2008-2011
Le Bonheur Small Grant. <b>Differences in Inbred Strains and Seizure Susceptibility Following Hypoxia in Neonatal Mice.</b> <u>Principal Investigator.</u>	2008
University of Tennessee Health Science Center Seed Grant. <b>Development of A Mouse Model of Hypoxia Induced Seizures.</b> <u>Principal Investigator.</u>	2007-2008
Miami Children's Hospital Research Institute Seed Grants. <b>Efficacy of Lamotrigine in a Neonatal Model of Hypoxic-Ischemic Injury.</b> <u>Principal Investigator.</u>	Aug. 2002-2004
American College of Clinical Pharmacy, CNS PRN. <b>Neuroprotection in Neonatal Ischemia and Hypoxia. Research Mini-sabbatical on Model of Neonatal Ischemia and Hypoxia, and Immunohistochemistry Techniques.</b> <u>Principal Investigator.</u> Mentor: Susan Fagan, PharmD, BCPS, FCCP., Professor of Neurology, Medical College of Georgia.	2002

## **Investigator Initiated**

Seizure Control and Quality of Life in Children after Vagal Nerve Stimulator Placement, Corpus Callosotomy or Ketogenic Diet Initiation. Sander Foundation <u>Co-Investigator.</u>	2014-2018
Special Needs Assessment and Plan Study (SNAP). <u>Co-Investigator.</u>	2014-2018
A Randomized Controlled Trial of Cognitive Behavioral Therapy and Hypnotherapy to Manage Pain in Pediatric Patients with Gastrointestinal Disease. <u>Co-Investigator.</u>	2014-2018
Evaluation of an Innovative Model of Care for Children with Complex Medical Needs. Seton Innovations Grant. <u>Co-Investigator.</u>	2014-2018
Efficacy of Sonicare Tooth Brush on Oral Hygiene for Cleft Palate and Lip in Patients 4-10 Years Old. Proctor and Gamble. <u>Co-Principal Investigator.</u>	2013-2017
Texas Survey of Best Practices in Epilepsy. <u>Co-Investigator.</u>	2012-2013
IV Lacosamide: The Safety of Intravenous Lacosamide. Shainberg Fund. <u>Co-Investigator.</u>	2009-2012

Genetic Susceptibility in Neonatal Hypoxia Induced Seizures-QTL Analysis. Le Bonheur Children's Medical Center Grant. <u>Principal Investigator</u> .	2008-2009
Development of a Neonatal Seizure Model of Hypoxia-Induced Seizures. University of Tennessee College of Pharmacy Seed Grant. <u>Principal Investigator</u> .	2007-2008
Rapid Infusion of Levetiracetam in Pediatric Patients. Shainberg Fund. <u>Co-Investigator</u> .	2007-2008
Two-year Follow-up Study Evaluating the Efficacy of Levetiracetam in Adult and Pediatric Patients with Epilepsy. <u>Principal Investigator</u> . Funded UCB Pharma, Inc.	2002-2003
Pharmacokinetics of Lamotrigine in the Mother and the Neonate. <u>Principal Investigator</u> . Funding by GlaxoSmithKline.	2001-2002
Post-Marketing Evaluation of Levetiracetam in Adult and Pediatric Outpatients. <u>Principal Investigator</u> . Funding UCB Pharma, Inc.	Feb. 2001-May 2001
Use of Lamotrigine in the Prevention of Epilepsy. <u>Principal Investigator</u> . Funding GlaxoSmithKline.	Feb. 2001
Economic Evaluation of Parental Phenytoin Product Use in a Tertiary Hospital. <u>Principal Investigator</u> . Funding Pfizer Pharmaceuticals, Inc.	Jan. 2001-2002
Pharmacokinetics of IV Valproate in Children with Epilepsy: A Preliminary Study, <u>Principal Investigator</u> , Funding Le Bonheur-University of Tennessee, Small Grant.	Jul. 1998-Jul. 2000
Appropriateness of Anticonvulsant Level Monitoring in A Pediatric Hospital, <u>Principal Investigator</u> .	Oct. 1998
Student vs. Preceptor Assessments During Fourth-Year Clinical Experiences, <u>Principal Investigator</u> .	Jan. 1995
<b>Private Industry Sponsor Studies (Phase 1-4) Clinical Drug Trials in Adults and Children (most therapeutic areas, emphasis in pediatrics, rare disease, and neurology). Oversaw 50 to &gt;200 studies annually. <u>Collaborating Investigator</u>.</b>	2000-2018
A 7-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Effects of Adjunctive Levetiracetam on the Sleep Architecture of Adult Subjects (18-45 years of Age) with Partial Onset Epilepsy Receiving a First Generation Anti-epileptic Drug. <u>Co-Investigator</u> .	Jun. 2002-2003
GlaxoSmithKline Inc., A Multi-center, Double-blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures. <u>Co-Investigator</u> .	Oct. 2001-2003



UCB Pharma, Inc., A Double-blind, Multi-center, Randomized, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Adjunctive Treatment with 3000 mg/day (pediatric target dose of 60 mg/kg/day) oral levetiracetam (LEV) (166, 20 and 500 mg tablets), in Adults and Pediatric Subjects (4-65 years) Suffering from Idiopathic Primary Generalized Tonic-Clonic (PGTC) Seizures. <u>Co-Investigator</u> .	Sept. 2001-2003
OrthoMcNeil Pharmaceuticals, Inc. A Comparative Study of Topamax (Topiramate) Verses Depakote (Valproate) in Subjects with Juvenile Myoclonic Epilepsy. CAPSS-107. <u>Co-Investigator</u> .	Feb. 2001-2003
GlaxoWellcome, Inc.. Open-Label, Uncontrolled Long-Term Study to Assess the Safety of Lamictal in Pediatric Subjects. LAM 20007. <u>Co-Investigator</u> .	Jan. 2001-2003
GlaxoWellcome, Inc.: A Double-Blind, Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics and Efficacy of Lamictal in Pediatric Age Subjects (1-24 Months) LAM 20006. <u>Co-Investigator</u> .	Jan. 2001-2002
GlaxoWellcome, Inc. Open-Label, Multicenter, Randomized Trial to Evaluate the Development of Components of Polycystic Ovary Syndrome (PCOS) in Female Subjects with Newly Diagnosed Epilepsy Initiating Anti-Epileptic Drug Treatment on either Lamotrigine or Valproate Monotherapy. <u>Co-Investigator</u> .	Dec. 2000-2003
Elan Pharmaceuticals, Inc. A Multicenter, Open-Label, Safety Study to Evaluate The Use of 25 mg and 50 mg Zonegran (Zonisamide) in the Initiation of Therapy in Patients With Epilepsy. <u>Co-Investigator</u> .	Dec. 2000-2001
Pfizer Pharmaceuticals: Pediatric Use of Amlodipine in the Treatment of Hypertension-2 Trial (PATH-2). A Population Pharmacokinetic Trial. <u>Principal Investigator</u> .	Dec. 1999-2000
Pfizer Pharmaceuticals: Pediatric Use of Amlodipine in the Treatment of Hypertension-I Trial (PATH-I). A randomized, double-blind, placebo-controlled, parallel group dose-ranging study to evaluate the efficacy and safety of amlodipine in the treatment of hypertension in children. <u>Co-Investigator</u> .	Dec. 1999-2000
Parke Davis: Gabapentin Pediatric Add-On Trial: A Randomize, Double-Blind Placebo Controlled, Parallel-Group, Multicenter Study in Patients With Partial Seizures, <u>Co-Investigator</u> .	Apr. 1999-Feb. 2000
Parke Davis: Open-Label, Safety Study of Gabapentin (CI-945) as Adjunct Therapy in Children Ages 1 Month Through 4 Years With Partial Seizures Uncontrolled by Current Anticonvulsant Drugs, <u>Co-Investigator</u> .	Mar. 1999-Jul. 2000

PPRU Network and UCSD: Evaluation of the Pharmacokinetics and Tolerance of Escalating Doses of Oral Pentoxifylline in Children with Acute Kawasaki Disease (IND# 48434), Co-Investigator. Mar. 1999-Oct. 2000

Parke Davis: An Open Label, Safety, Tolerance, and Pharmacokinetic Study of Intravenous and Intramuscular Fosphenytoin (Cerebryx<sup>®</sup>) in Children < 5 Years of Age, Co-Investigator. Apr. 1998-May 2000

## **PUBLICATIONS**

---

### **Peer-reviewed publications**

Greenberg R, McCune S, Attar S, **Hovinga C**, Stewart B, Lacaze-Masmonteil T. Pediatric clinical trial networks: Role in accelerating development of therapeutics in children. *Ther Innov Regul Sci*. (In press).

Mulberg A, Conklin LS, Croft N, Parkish A, Bousvaros A, DeZoeten E, Dubinsky M, Carpi F, Escher H, Vesely R, Ollivier C, Crandall W, **Hovinga C**. Pediatric Extrapolation of Adult Efficacy Is Critical for Efficient and Successful Drug Development. *Gastroenterology* 2022 Online <https://doi.org/10.1053/j.gastro.2022.03.018>

Noel GK, Nelson RM, Bucci-Rechtweg C, Portman R, Miller T, Green DJ, Snyder D, Moreno C, **Hovinga C**, Connor E. Inclusion of adolescents in adult clinical trials: Report of the Institute for Advanced Clinical Trials for Children's Pediatric Innovation Research Forum. *Ther Innov Regul Sci*. 2021; 2:1-6.

Cadmus SD, Sebastian KR, Warren D, **Hovinga CA**, Croce EA, Reveles LA, Levy ML, Diaz LZ. Efficacy and patient opinion of wet-wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: A randomized split-body control study. *Pediatric Dermatology*. 2019; 36:437-41.

Gupte-Singh K, Wilson JP, Barner JC, Richards KM, Rascati KL, **Hovinga C**. Patterns of antiepileptic drug use in patients with potential refractory epilepsy in Texas Medicaid. *Epilepsy Behavior*. 2018; 87:108-16.

Zhu TH1, Werchan IA, Escamilla KV, Sebastian K, **Hovinga CA**, Reichenberg JS. Association Between Delusions of Infestation and Prescribed Narcotic and Stimulant Use. *J Psychiatry Practice*. 2018; 24:428-431.

Pickel S, Shen MW, **Hovinga C**. Look Who's Talking: Comparing Perceptions Versus Direct Observations in Family-Centered Rounds. 2016; 6:387-93.

Wilkinson M, King B, Iyer S, Higginbotham E, Wallace A, **Hovinga C**, Allen C. Comparison of a rapid albuterol pathway with a standard pathway for the treatment of children with a moderate to severe asthma exacerbation in the emergency department. *Journal of Asthma*. 2017; 26:1-8.

Rivkin MJ, deVeber G, Ischord RN, Kirton A, Chan AK, **Hovinga CA**, Gill JC, Szabo A, Hill MD, Scholz K, Amlie-Lefond C. Thrombolysis in Pediatric Stroke study. *Stroke*. 2015; 46:880-5.

Bernard TJ, Rivkin MJ, Scholz K, deVeber G, Kirton A, Gill JC, Chan AK, **Hovinga CA**, Ichord RN, Scholz K, Grotta JC, Jordan LC, Benedict S, Friedman NR, Dowling MM, Elbers J, Torres M, Sultan S, Cummings DD, Grabowski EF, McMillan HJ, Beslow LA, Amlie-Lefond C. Emergence of the primary pediatric stroke center: impact of the thrombolysis in pediatric stroke trial. *Stroke*. 2014; 45:2018-23.

Krushkal J, Murphy LE, Palmer FB, Graff JC, Sutter TR, Mozhui K, **Hovinga C**, Thomas F, Park V, Tylavsky FA, Adkins RM. Epigenetic analysis of neurocognitive development at 1 year of age in a community practice based pregnancy cohort. *Behavior Genetics*. 2014; 44:113-25.

Ilo E and **Hovinga CA**. Extended-release antiepileptic drugs: A comparison of pharmacokinetic parameters relative to original immediate-release formulations. *Epilepsia*. 2013; 54: 28-35.

Harden CL, Pennell PB, Koppel BS, **Hovinga CA**, Gidal B, Meador KJ, Hopp J, Ting TY, Hauser WA, Thurman D, Kaplan PW, Robinson JN, French JA, Wiebe S, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Shafer PO, Le Guen C. Practice Parameter update: Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): Vitamin K, folic acid, blood levels, and breastfeeding. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. *Neurology*. 2009; 73:142-9.

Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, **Hovinga CA**, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C. Practice Parameter update: Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): Teratogenesis and perinatal outcomes. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. *Neurology*. 2009; 73:133-41.

Harden CL, Hopp J, Ting TY, Pennell PB, French JA, Hauser WA, Wiebe S, Gronseth GS, Thurman D, Meador KJ, Koppel BS, Kaplan PW, Robinson JN, Gidal B, **Hovinga CA**, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Le Guen C. Practice Parameter update: Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): Obstetrical complications and change in seizure frequency. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. *Neurology*. 2009; 73:126-32.

Harden CL, Pennell PB, Koppel BS, **Hovinga CA**, Gidal B, Meador KJ, Hopp J, Ting TY, Hauser WA, Thurman D, Kaplan PW, Robinson JN, French JA, Wiebe S, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Shafer PO, Le Guen CL; American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Epilepsia*. 2009; 50:1247-55.

Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, **Hovinga CA**, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C; American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Epilepsia*. 2009; 50(5):1237-46.

Harden CL, Hopp J, Ting TY, Pennell PB, French JA, Allen Hauser W, Wiebe S, Gronseth GS, Thurman D, Meador KJ, Koppel BS, Kaplan PW, Robinson JN, Gidal B, **Hovinga CA**, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Le Guen C; American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Epilepsia*. 2009; 50:1229-36.

Asato MR, Manjunath R, Seth RD, Phelps SJ, Wheless JW, **Hovinga CA**, Pina-Garza JE, Haskins LS, Zingaro WM. Adolescent and caregiver experiences in epilepsy. *Journal of Child Neurology*. 2009; 24:562-71.

Wheless JW, Clarke D, **Hovinga CA**, Ellis M, Durmeier M, McGregor A, Perkins F. Rapid Infusion of a Loading Dose of Intravenous Levetiracetam With Minimal Dilution: A Safety Study *Journal of Child Neurology*. 2009; 24:946-51.

Amlie-Lefond C, deVeber G, Chan A, **Hovinga CA**, Benedict S, Bernard T, Carpenter S, Dowling M, Fullerton H, Kirkton A, Lo W, Carpenter J, Zamel K, Ichord R. International Pediatric Stroke Study. Use of tPA in Childhood Arterial Ischemic Stroke. *Lancet Neurology*. 2009; 8:530-6.

Amlie-Lefond C, Chan AK, Kirkton A, deVeber G, **Hovinga CA**, Ichord R, Stephens D, Zaidat OO. Thrombolysis in acute childhood stroke: design and challenges of the thrombolysis in pediatric stroke clinical trial. *Neuroepidemiology*. 2009; 32: 279-86.

**Hovinga CA** Pennell PB. Antiepileptic drugs therapy in pregnancy II: fetal and neonatal exposure. *International Review of Neurobiology*. 2008; 83: 241-58.

Pennell PB, **Hovinga CA**. Antiepileptic drugs therapy in pregnancy I: gestation-induced effects on AED pharmacokinetics. *International Review of Neurobiology*. 2008; 83: 227-40.

Whelan HT, Cook JD, Amlie-Lefond C, **Hovinga CA**, Chan A, Ichord RN, deVeber G. Practical model-based dose-finding study in early phase clinical trials: Optimizing tPA dose for treatment of ischemic stroke in children. *Stroke*. 2008; 39:2627-36.

Wheless JW, Asato MS, Sheth RD, **Hovinga CA**, Phelps SJ, Pina-Garza JE, Manjunath R, Haskins LS. Seizure Emergency Plans: Results from a Cross Sectional-Epilepsy Survey. *Epilepsy Behav*. 2008; 13: 489-93.

**Hovinga CA**, Asato MR, Manjunath R, Wheless JW, Phelps SJ, Sheth RD, Pina Garza JE, Zingaro WM, Haskins LS. Association of Non-Adherence to Anti-Epileptic Drugs and Seizures, Quality of Life, and Productivity: Survey of Patients with Epilepsy and Physicians. *Epilepsy & Behavior*. 2008; 13: 316-22.

**Hovinga CA**, Ravina BR, DeProspero N, Bain L, Blumenstein R, Tobin A. Sytematic Evaluation of Therapeutics for Huntington's Disease (SET-HD): A Systematic Assessment for Neuroprotective Agents. <http://www.huntingtonproject.org/Default.aspx?tabid=50>

Girish H, Kotagal P, **Hovinga CA**, Wyllie E, Morris H. Carbamazepine Elevation in A Group of Patients and the Role of Fentanyl. *Seizure*. 2005; 14:312-7.

**Hovinga CA**. Valrocecide (Teva/Acorda). *Current Opinion in Investigational Drugs*. 2004; 5:101-6.

Lardizabal DV, Luders HO, **Hovinga CA**, Bourgeois BF. Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction. *Neurology*. 2004; 62:161.

Srikijvilaikul T, Najm IM, **Hovinga CA**, Gonzalez-Martinez J, Bingaman WE. Seizure Outcome Following Temporal Lobectomy In Temporal Lobe Cortical Dysplasia. *Epilepsia*. 2003; 44:1420-4.

Ravina BM, Fagan SC, Hart RG, **Hovinga CA**, Murphy DD, Marler JR. Neuroprotective Agents for Clinical Trials in Parkinson's Disease: A Systematic Assessment. *Neurology*. 2003; 60:1234-40.

Lazdizabal DV, Morris HH, **Hovinga CA**, Carreno M. The Tolerability and Pharmacokinetics of Oral Loading with Lamotrigine in Epilepsy Monitoring Units. *Epilepsia*. 2003; 44:536-9.

**Hovinga CA**. SPM-927 (Schwarz Pharma). *IDrugs*. 2003; 6:479-85.

**Hovinga CA**. Erlosamide. *IDrugs (Iddb)-Ashley Publishing*. <http://iddb.com>, Accessible March 3, 2003.

**Hovinga CA**, Rose DF, Phelps SJ. Appropriateness of Anticonvulsant Level Monitoring in A Pediatric Hospital. *Journal of Pediatric Pharmacology and Therapeutics* 2003; 8:200-9.

**Hovinga CA**. Invited Review-Promising Investigational Anticonvulsant Drugs. *Expert Opinion on Investigational Drugs*. 2002; 10:1387-406.

**Hovinga CA**. Levetiracetam: A Novel Antiepileptic Medication. *Pharmacotherapy*. 2001; 21:1375-88.

Chaffin CC, **Hovinga CA**, Phelps SJ. Clonidine in the Treatment Attention- Deficit Hyperactivity Disorder. *Journal of Pediatric Pharmacy Practice* 1999; 4: 308-315.

**Hovinga CA**, Chicella MF, Rose DF, Eades SK, Dalton JT, Phelps SJ. Use of Intravenous Valproate in Three Pediatric Patients with Nonconvulsive or Convulsive Status Epilepticus. *Annals of Pharmacotherapy* 1999; 33: 579-584.

Phelps SJ, **Hovinga CA**, Rose DF, Vaughn C, Olsen-Creasy K. The Ketogenic Diet in Pediatric Epilepsy. *Nutrition in Clinical Practice* 1998; 13(6): 267-282.

## **Books & Chapters**

**Hovinga CA**. Principles of Pharmacokinetics and Pharmacogenomics of Anticonvulsants. Advances in the Treatment of Epilepsy. 1st Ed. Baumgartner JE, Wheless JW, Ed. New York, NY: Elsevier. 2008.

Phelps SJ, **Hovinga CA**, Wheless JW. Status Epilepticus. In: Dipiro J, Talbert R, Yee G, et al, eds. Pharmacotherapy: A Pathophysiological Approach. 7th ed. New York, NY: McGraw Hill. 2008.

Phelps SJ, **Hovinga CA**, Boucher BA. Status Epilepticus. In: Dipiro J, Talbert R, Yee G, et al, eds. Pharmacotherapy: A Pathophysiological Approach. 6th ed. New York, NY: McGraw Hill. 2006.

**Hovinga CA**, Lachhwani D. Treatment of Epilepsy. In: Moodie D, Sabella D, eds. The Cleveland Clinic Comprehensive Pediatric Board Review Book, 2nd Ed.. New York, NY. Lippincott Williams and Williams, 2005.

**Hovinga CA**, Wyllie E. Treatment of Epilepsy. In: Moodie D, Sabella D, eds. The Cleveland Clinic Comprehensive Pediatric Board Review Book. New York, NY. Lippincott Williams and Williams, 2002.

Phelps SJ, **Hovinga CA**, Boucher BA. Status Epilepticus. In: Dipiro J, Talbert R, Yee G, et al, eds. Pharmacotherapy: A Pathophysiological Approach. 5th ed. New York, NY: McGraw Hill, 2002.

**Hovinga CA**. Antiepileptics, Anti-microbials, Opioid Monographs. In: Phelps SJ, ed. Guidelines for Administration of Intravenous Medications to Pediatric Patients, AJHP, 2001.

**Hovinga CA**, Phelps SJ. Attention Deficit Disorder. In: Herfinal E, Gourley D, eds. Textbook of Therapeutics; Drug and Disease Management, 7th ed. Baltimore, MD: Williams & Williams. May 2000.

**Hovinga CA**, Phelps SJ. Pediatric Epilepsy. In: Heusman B, ed. Pediatric Care Module. Pharmacotherapy Self-Assessment Program III. Kansas City, MO: American College of Clinical Pharmacy. January 2000.

## **Non-peer-reviewed publications**

**Hovinga CA**. Anticonvulsant Mechanisms of Action. Neurospark, July 2011.

**Hovinga CA**. Medication Dosing in Pediatric Patients, A Careful Look at the Therapeutic Orphan. Neuroscience Pathways, March 2003.

**Hovinga CA**. What is All the Fuss about Ritalin? JPPT. 2001; 37:304-5.

**Hovinga CA**. Antiepileptic Drug Approval In Children: Where Are We Now?. American Epilepsy Society News. 2001; 10:1-6.

**Hovinga CA.** Role of Carnitine Supplementation During Valproate Therapy. Cleveland Foundation Epilepsy Newsletter, Spring 2001 Edition.

**Hovinga CA.** Singulair-A New Drug for Asthma. Le Bonheur Capsule 1998 Spring Edition.

**Hovinga CA.** Topiramate. Le Bonheur Capsule 1997 Fall Edition.

### **Non-print / Online materials**

**Hovinga CA.** Acetazolamide. In: Panayiotopoulos C., ed. Atlas of Epilepsies. <http://www.springer.com>, 2009.

**Hovinga CA.** Systematic Evaluation of Treatments for Huntington's Disease. <http://www.huntingtonproject.org/Default.aspx?tabid=50>

**Hovinga CA.** Advances in the Treatment of Epilepsy. ASHP Annual Meeting Course 2004. Published <http://ashp.omnibooksonline.com/2004/papers/PI-166.pdf>, Program #204-000-04-262-L01.

**Hovinga CA.** New Agents in the Treatment of Pediatric Epilepsy. ASHP Annual Meeting Course 2004. Published <http://ashp.omnibooksonline.com/2004/papers/PI-117.pdf>, Program #204-000-04-243-L01.

### **Invited Reviews**

Pharmacotherapy Self-Assessment Program: Neurology Module 4<sup>th</sup> Edition by American College of Clinical Pharmacy, 2001-2002.

Natural Products Explorer CD-ROM, 1<sup>th</sup> Edition by Facts & Comparisons. Doody Publishing 2000.

Medicinal Chemistry Tutorial, 1<sup>st</sup> Edition. by Roche V. Doody Publishing, 2000.

Pediatric Dosage Handbook 1999-2000, 6<sup>th</sup> Edition by Taketomo CK, Hodding JH, Kraus DM. Doody Publishing, 1999.

### **Ad Hoc Reviewer**

ACCP PSAP Pediatric Review Board  
Annals of Pharmacotherapy  
Expert Opinion in Investigational Drugs  
iDrugs  
Journal of Pediatric Pharmacotherapy (and Board of Technical Consultants)  
Journal of Pharmacy Technology  
Lancet Neurology  
Pediatric Neurology  
Pharmacotherapy  
Therapeutic Innovation and Regulatory Science Journal

## Editorial Responsibilities

<b>Lexicomp Drug Information and Handbooks</b> Content Advisor, Neurology and Pediatrics	2003-present
<b>Cochrane Review-Epilepsy Group, Liverpool, UK</b>	2010-2011

## INVITED PRESENTATIONS

---

### International

Use of Real World Evidence in Neonatal Clinical Trials. <b>International Neonatal Consortium Meeting</b> , Virtual.	Oct. 29, 2021
Infrastructure Needs: How Do We Create and Sustain a Network for the Conduct of Ethical Pediatric Trial? <b>Harvard MRCT NIH R13 Conference on Pediatric Global Trials</b> . Virtual.	Sept. 31, 2021
Real World Data: Use in Pediatric Drug Development <b>Third Annual Pediatric Summit Meeting, Bayer Pharmaceuticals</b> . Virtual.	Feb 8, 2021
United States Pediatric Clinical Trial Preparedness During COVID-19. <b>Enpr-EMA Annual Meeting</b> , Virtual.	Sept. 28, 2020
Institute for Advanced Clinical Trials in Children-Update on the US Perspective, <b>C4C Launch Meeting</b> , Berlin, Germany	May 15, 2018
SET-HD: Rationale and Progress. <b>European Huntington's Disease (Euro-HD) Network</b> , Aachen, Germany.	Jan. 30, 2005
SET-HD: High Output Screening in Neurodegenerative Diseases. <b>Euro-HD Network</b> , Aachen, Germany.	Jan. 29, 2005

### National

Co-creation: Ensuring Patients Are At the Heart of Trial Design. <b>Reuters Events Pharma Clinical 2022</b> . Virtual.	May 18, 2022
Real World Data Focus on Neonatology, SOCRA Pediatric Trial Conference.	May 5, 2022
Study Methodologies in Pediatric Clinical Trials. <b>New Horizons in Pediatric Drug Development Conference</b> . Cetera.	Oct. 22, 2021
Platform Trials Application to Pediatric Rheumatological Conditions. <b>Pediatric Rheumatology Clinical Study Group (PRCSG) Advisory Council Meeting</b> . Virtual.	Feb 5, 2021



Epidemiology of Common Adolescent Medical Diagnosis. <b>I-ACT for Children Pediatric Research Innovation Forum.</b> , Bethesda, MD.	Oct. 15, 2020
Practical Aspects of Gene Therapy Trials, <b>SOCRA Annual Meeting</b> , Virtual.	Sept. 25, 2020
COVID-19 in Pediatric Populations. <b>I-ACT for Children’s Developing Pediatric Treatments for COVID-19 Workshop</b> , Virtual.	May 28, 2020
Learning Networks Applied to Pediatric Clinical Trials, <b>I-ACT for Children’s Design Meeting</b> , Chicago, IL	Mar. 28, 2019
Pediatric Device Trials: Where are We Know?, <b>SOCRA Pediatric Conference</b> , St. Pete Beach, CA.	Feb. 27, 2019
Pediatric Research Innovation, <b>PPHNet Annual Meeting</b> , San Francisco, CA	Feb. 2, 2019
The Duchenne Muscular Dystrophy Platform Trial (DPT), <b>Parent Project Muscular Dystrophy Annual Meeting</b> , Orlando FL.	Jan. 20, 2018
Use of Cannabidiol in Pediatric Epilepsy: Current Evidence. <b>American Society of Health-System Pharmacy Midyear Meeting</b> . Orlando, FL.	Dec. 5, 2017
Counseling Women with Epilepsy on the use of Anti-Epileptic Drugs during Pregnancy. <b>American Colleges of Clinical Pharmacy Annual Meeting</b> . Phoenix, AZ.	Oct. 9, 2017
Toxin Safety Zone for Patients and Practitioners: A Practice Safety Review for Providers Injecting any Pediatric and Adolescent Hypertonia. <b>American Academy of Physical Medicine and Rehabilitation Annual Assembly</b> . New Orleans, LA.	Oct. 21, 2017
Toxin Safe Territory for Both Patients and Providers. <b>American Academy for Cerebral Palsy and Developmental Medicine</b> . Annual Meeting. Austin, TX.	Sept. 23, 2017
How to Incorporate Research into Child Practice. <b>Child Life Council Annual Conference on Specialty Issues</b> . Cincinnati, OH.	May 24, 2015
Neurology Board Review. <b>Pediatric Pharmacy Advocacy Group Annual Meeting</b> , Minneapolis, MN.	May 1, 2015
Autism Spectrum Disorders: Update on Diagnosis and Treatment. <b>American College of Clinical Pharmacy Annual Meeting</b> . Hollywood, FL.	Oct. 23, 2012

New Anticonvulsants and Their Role in Pediatric Epilepsies. <b>American Society of Health-System Pharmacists Midyear Meeting.</b> Anaheim, CA.	Dec. 7, 2010
The Pharmacogenomics of the New Generation Antiepileptics as They Relate to Different Pediatric Patients (from Neonate to Adolescent). <b>American College of Clinical Pharmacy Annual Meeting.</b> San Antonio, TX.	Oct. 19, 2010
Pharmacogenomics of Pediatric Epilepsy. <b>Pediatric Pharmacy Advocacy Group Spring Meeting.</b> Salt Lake, UT.	Apr. 16, 2010
Update on the Pharmacotherapy of Pediatric Epilepsy. <b>American College of Clinical Pharmacy Spring Meeting.</b> Phoenix, AZ.	Apr. 8, 2008
Anticonvulsants and Fertility, Pregnancy and Lactation. <b>American College of Clinical Pharmacy Annual Meeting.</b> Denver, CO.	Oct. 14, 2007
Neonatal Clinical Trials and Pharmacology. Workshop in Neonatal Seizure Trials. <b>NIH/NINDS.</b> Bethesda, MA.	
Ups and Downs of Anticonvulsant Therapy. Clinical Controversies in the Epilepsy Monitoring Unit. Professionals in Healthcare Symposium. <b>The American Epilepsy Society and American Neurophysiology Society Annual Meeting.</b>	Dec. 2, 2005
Systematic Evaluation of Treatments for Huntington's Disease. The HD Therapeutics Pipeline: From Drug Discovery to Clinical Trials Symposium. <b>Presented at the NIH/NINDS Study Section.</b> Philadelphia, PA.	Oct. 19, 2005
Disease Modification Therapy for Neurodegenerative Disease. <b>Potential Therapies for Huntington's Disease Conference.</b> HiQ Foundation, New York City, NY.	Aug. 24, 2005
Advances in the Treatment of Epilepsy. <b>American Society of Health-System Pharmacists Annual Meeting,</b> Orlando, FL.	Dec. 8, 2004
Use of the New Anticonvulsants in Children. PPAG Symposium, <b>American Society of Health-System Pharmacists Annual Meeting,</b> Orlando, FL.	Dec. 9, 2004
Translational Research In Neuroprotection Antiepileptogenesis. <b>American Epilepsy Society Annual Meeting.</b> New Orleans, LA.	Dec. 6, 2004

Systematic Evaluation of Treatments for Huntington's Disease (SET-HD): Updates of the First 10 Compounds. <b>Presented at the NIH/NINDS Study Section Meeting.</b> St. Louis, MO.	Nov. 4, 2004
<b>Clinical Neurology Pediatric Annual Conference XXV</b> , Miami Children's Hospital Brain Institute, Miami, FL	May 8, 2004
Neuroprotection in Parkinson's Disease. CINAPS. <b>American College of Clinical Pharmacy.</b> Atlanta, GA.	Nov. 4, 2003
New Antiepileptic Drug Therapy: A Decade Later. Where Are We Now? Ohio College of Clinical Pharmacy. Cleveland, OH.	Oct. 8, 2003
Pharmacotherapy of Attention Deficit Hyperactivity Disorder. <b>Pediatric Advocacy Annual Conference.</b> Dana Point, CA.	Oct. 3, 2003
Treatment of Refractory Neonatal Seizures. <b>Pediatric Pharmacology Advocacy Group Neonatal Specialty Conference.</b> Tucson, AZ.	Apr. 6, 2002
Neurodevelopment of the Preterm Neonate. <b>Pediatric Pharmacology Advocacy Group Neonatal Specialty Conference.</b> Tucson, AZ.	Apr. 6, 2002
Treatment of Status Epilepticus. <b>Medical College of Georgia, Grand Rounds.</b> Augusta, GA.	Mar. 10, 2003
Pediatric Neuroprotection: Mini-Sabbatical Experience. <b>CNS PRN, American College of Clinical Pharmacy</b> , Fall Meeting. Albuquerque, NM.	Oct. 21, 2002
Can Medications Prevent Epilepsy? <b>Pediatric Pharmacotherapy Advocacy Group</b> , Annual Meeting. St Petersburg, FL.	Oct. 2, 2002
Molecular Mechanisms of Drug Resistance in Epilepsy. <b>Bethel-Cleveland Clinic Foundation International Symposium.</b> Cleveland, OH.	May 19, 2002
Antiepileptic Drug Use in Women with Epilepsy: Case Studies-Panel. <b>Cleveland Clinic Foundation Comprehensive Course.</b> Painesville, OH.	May 18, 2002
Drug Interactions: Case Studies-Panel. <b>Cleveland Clinic Foundation Comprehensive Course.</b> Painesville, OH.	May 18, 2002
Developmental Pharmacokinetics of Antiepileptic Medications. <b>Cleveland Clinic Foundation Comprehensive Course.</b> Painesville, OH.	May 18, 2002

Side Effects of Antiepileptic Medications: Case Studies. **Cleveland Clinic Foundation Comprehensive Course**. Painesville, OH. May 17, 2002

Antiepileptic Medications in Clinical Practice. **Neuroscience National Symposium**. Cleveland, OH. Nov. 14, 2001

Antiepileptic Medication Selection: Case Studies. **Ohio College of Clinical Pharmacy**, Independence, OH. May 4, 2001

New Antiepileptic Medications. **Ohio College of Clinical Pharmacy**, Independence, OH. May 4, 2001

A Practical Approach to the Ketogenic Diet. **American Society of Parental and Enteral Nutrition Annual Meeting**, Nashville, TN. Jan. 24, 2000

### **Regional**

Neonatal Seizures and Stroke, **Northern Ohio Neonatal Nursing Symposium**. Westlake, OH. Oct. 16, 2006

### **OTHER PRESENTATIONS, POSTERS, AND ABSTRACTS**

---

#### **International**

Wittenberg BA, Johnson J, Wirth K, **Hovinga C**. Inclusion of Family Advisors as Primary Investigators in Research Studies. The 6th International Conference on Patient-and Family-Centered Care in Vancouver, British Columbia, Canada. Abstract #0298-000318. Aug. 7, 2014

#### **National**

**Hovinga C**, Neely D, Bradley J, Nambiar S, Noel G. Characterization of Published Information Available for Informing Treatment of Children with Serious Infections with Antibacterials Approved for Use in Adults but Have Not Yet Been Labeled for Use in Children. American Society of Microbiology, Annual Meeting, Washington, DC. Platform/Abstract 4311. Jun.11, 2022

Gluck A, Davies A, McDonald J, Maltenfort M, Mitsnefes M, Dharnidharka V, Dixon, B, Flynn T, Somers M, Smoyer W, Neu A, **Hovinga C**, Skversky A, Eissing T, Kaiser A, Breitenstein S, Furth S, Forrest C, Denburg. Using Electronic Health Records to Evaluate Kidney Function Decline in Children with Chronic Kidney Disease. American Society of Nephrology Annual Meeting, Orlando, FL. Platform/Abstract SA-OR43. Nov. 6, 2021

- Hovinga C**, Berry S, Larkindale J, Bronson A, Litvinchuk D, Ascheim D, Connor E. Improving Clinical Trials in Duchenne Muscular Dystrophy By Using A Novel Platform Study Approach., MDA Foundation Clinical and Scientific Annual Meeting. Orlando, FL, Abstract 41. Jul. 2019
- Hovinga C**, Benson L BS, Allen J, McConoughey S, O'Brien V, Connor E, Survey of Pediatric Device Trial Experience Within the I-ACT for Children Research Network. SOCRA Pediatric Conference, St. Pete, CA, Abstract 2.1 Feb. 2019
- Hovinga C**, Berry S, Larkindale J, Bronson A, Litvinchuk D, Ascheim D, Connor E. Improving Clinical Trials in Duchenne Muscular Dystrophy By Using A Novel Platform Study Approach., Parent Project Muscular Dystrophy. Clinical Meeting. Orlando, FL, Abstract 23. Jan. 2018
- Titus JB, **Hovinga C**, Kime K, Bower N, Perkins F, Clarke D. Physicians' Perspectives in Utilizing Neuropsychological Services in Pediatric Patients With Epilepsy. American Epilepsy Society Annual Meeting. San Diego, CA. Abstract 2.291. Dec. 2012
- Watson M, Clarke DF, **Hovinga C**, Nussbaum N. The Use of Passive Functional MRI in Presurgical Planning for Pediatric Patients with Epilepsy. American Epilepsy Society Annual Meeting. San Diego. Abstract 2.161. Dec. 2012
- Hovinga CA**, Kime K, Bower NR, Titus JB, Perkins FF, Clarke DF. Knowledge of Physicians and Practice Parameters Pertaining to the Diagnosis and Drug Management of Pediatric Epilepsy. American Epilepsy Society Annual Meeting. San Diego. Abstract 1.343. Dec. 2012
- Perkins F, Kime K, Bower N, **Hovinga CA**, Titus JB, Clarke DF. Physicians Practices for Epilepsy Surgery in Pediatrics. American Epilepsy Society Annual Meeting. San Diego. Abstract 1.342. Dec. 2012
- Pickel SF, Shen MW, **Hovinga CA**. Look Who's Talking: A Comparison of Perceptions Versus Objective Observations During Family Centered Rounds. Pediatric Academic Society. Boston, MA. Abstract 3821.301. Apr. 30, 2012
- Tylavsky F, **Hovinga C**, Murphy L, Graff C, Palmer F, Thomas F, Park V, Connor P, Volgyi E, Adkins R, Krushkal J. Genetic and Epigenetic Analysis of Early Childhood Phenotypic Outcomes in a Community-Based Longitudinal Cohort in Memphis, TN: The CANDLE Study. Heidelberg, Germany. *Genetic Epi.* 2012;36:159. Sept. 2011

- Pont SJ, Sage WM, Ripley , Millea S, Rao M, **Hovinga CA**, Kelder SH. May 25, 2012  
Mapping Child Fitness and Obesity: Leveraging data sharing and public reporting to mobilize system change. Platform. Austin, TX Annual Conference of the International Society for Behavioral Nutrition and Physical Activity (ISBNPA).
- Manjunath R, Asato M, Wheless J, Sheth R, **Hovinga C**, Phelps S, Pina-Garza E, Haskins L , Zingaro W. Dec. 2008  
Burden of Epilepsy In Adolescents and Their Care Givers. American Epilepsy Society Annual Meeting. Seattle, WA.. *Epilepsia*. 2008; 49: 165.
- Wheless J, **Hovinga C**, Clarke D, McGregor A, Perkins F, Durmeier M. Dec. 2008  
Rapid Infusion of Loading Dose of Intravenous Levetiracetam with Minimal Dilution: A Safety Study. American Epilepsy Society Annual Meeting. Seattle, WA. *Epilepsia*. 2008; 49: 109.
- Hovinga CA\***, Foldvary-Shaefer N, Syed T, Riley J. Dec. 2007  
Lamotrigine Pharmacokinetics in Lactation and in the Neonate. American Epilepsy Society Annual Meeting. Seattle, WA. *Epilepsia*. 2008; 49: 97.
- Foldvary-Shaefer N, **Hovinga CA**, Riley J, Syed T, Suciu GP. Dec. 2007  
Pharmacokinetics of Lamotrigine in Pregnancy: Correlation of Serum and Salivary Concentrations. American Epilepsy Society Annual Meeting. Philadelphia, PA. *Epilepsia*. 2007; 48: 337.
- Wheless JW, Asato MS, Sheth RD, **Hovinga CA**, Phelps SJ, Pina-Garza JE, Manjunath R, Haskins LS. Dec. 2007  
Prevalence and Description of Seizure Plans in Adult US Population. American Epilepsy Society Annual Meeting. Philadelphia, PA. *Epilepsia*. 2007; 48: 342.
- Hovinga CA\***, Asato MS, Sheth RD, Wheless JW, Phelps SJ, Pina-Garza JE, Manjunath R, Haskins LS. Dec. 2007  
Impact of Non-Adherence to Anti-Epileptic Drugs on Seizure Activity, Quality of Life, and Productivity. American Epilepsy Society Annual Meeting. Philadelphia, PA. *Epilepsia*. 2007; 48: 333.
- Phelps SJ, Asato MR, Wheless JW, **Hovinga CA**, Pina-Garza JE, Manjunath R, Haskins LS. Dec. 2007  
Comparison of Neurologists and Patient Perceptions of Adherence of Epilepsy. American Epilepsy Society Annual Meeting. Philadelphia, PA.. *Epilepsia*. 2007; 48: 334.
- Hovinga CA\***, Phelps SJ, Asato MS, Sheth RD, Wheless JW, Pina-Garza JE, Manjunath R, Haskins LS, Zingaro W. Nov. 2007  
Neurocognitive and Behavioral Factors Associated with Antiepileptic Drug Nonadherence. American College of Clinical Pharmacy Annual Meeting. *Pharmacotherapy*. 2007; 29:1497

- Donald D, **Hovinga CA**, Lee K, Bobo K. Evaluation of Enoxaparin in Pediatric Patients. Pediatric Pharmacology Midyear Meeting. Austin, TX. Mar. 31, 2007
- Sahni J, **Hovinga CA**, Lee K. Aprotinin in Pediatric Cardiopulmonary Bypass. Pediatric Pharmacology Midyear Meeting. Austin, TX. Mar. 31, 2007
- Lefond CA,, Chan A, **Hovinga CA**, DeVeber G, Ichord B. Thrombolysis in children with arterial ischemic stroke: International results from the International Pediatric Stroke Study. International Stroke Conference 2007, Kissimmee, FL. Feb. 16, 2007
- Ravina B, DiProspero N,, Fagan SC, Fischbeck K, Harrison M , Hart R, Heemskerk J, Murphy D, Profenno L, Blumenstein R, Signer ER, Taylor P, Tretheway JA,. **Hovinga CA**. Systematic Evaluation of Treatments for Huntington's Disease (SET-HD): An Interim Report. Presented as a platform at HD 2004: Changes, Advances and Good News (CAG)n" to the Hereditary Disease Foundation Annual Meeting, Boston, MA. Aug. 15, 2004
- Hovinga CA\***, Loddenkemper T, Holland KD, Chapman K, Shigeto H, Burrier C, Kellinghaus C. Assessment of the Antiepileptogenic Properties of Lamotrigine in a Hippocampal Stimulation Model of Prolonged Status Epilepticus. American Epilepsy Society Annual Meeting, Boston, MA. *Epilepsia*. 2003; 44 (Suppl. 9):201. Dec. 10, 2004
- Hovinga CA\***. Efficacy and Safety of Levetiracetam in Children: A 2-Year Experience. Presented at the American College of Clinical Pharmacy Annual Meeting, Atlanta, GA. Nov. 3, 2003
- Srikijvilaikul T, **Hovinga CA**, Bingaman WE, Najm IM. Seizure Outcome Following Temporal Lobectomy in Temporal Lobe Cortical Dysplasia. Presented Annual Meeting of the American Epilepsy Society Annual Meeting, Seattle, WA. Dec. 11, 2002
- Serje A, **Hovinga CA**, Morris H, Merner K. A Pharmacokinetic Based Method for Conversion of Patients from Valproate to Lamotrigine Monotherapy. Presented Annual Meeting of the American Epilepsy Society Annual Meeting, Seattle, WA. Dec. 9, 2002
- Hovinga CA\***, Morris H, Holland K, Foldvary N, Kotagal P, Wyllie E. Levetiracetam's Efficacy in Adults and Children. Platform presentation at Annual Meeting of the American Epilepsy Society Annual Meeting, Philadelphia, PA. *Epilepsia* 2001; 42 (Suppl 7). F.08. Dec. 4, 2001
- Lazdizabal DV, Morris HH, **Hovinga, CA**, Carreno M. The Tolerability and Pharmacokinetics of Oral Loading with Lamotrigine in Epilepsy May 14, 2001

Monitoring Units. Presented at Neuroscience Research Day, Cleveland Clinic Foundation, Cleveland, OH.

Lazdizabal DV, Morris HH, **Hovinga CA**, Carreno M. The Tolerability and Pharmacokinetics of Oral Loading with Lamotrigine in Epilepsy Monitoring Units. *Neurology*. 56 (Suppl. 3): A333. Apr. 2001

Girish H, Kotagal P, **Hovinga CA**, Wyllie E, Morris H. Carbamazepine Elevation in A Group of Patients and the Role of Fentanyl., *Neurology*. 2001; 56 (Suppl. 3): A236. Apr. 2001

**Hovinga CA\***, Rose DF, Phelps SJ. Appropriateness of Anticonvulsant Level Monitoring in A Pediatric Hospital. Poster presentation at the Annual Meeting of the American Epilepsy Society Annual Meeting, Orlando, FL. *Epilepsia* 1999; 40 (S7):121. Dec. 1999

**Hovinga CA\***, Chicella M, Rose DF, Eades SK, Dalton J, Phelps SJ. Use of Intravenous Valproate In Two Pediatric Patients With Convulsive Status Epilepticus, presentation PPAG Annual Clinical Meeting, Kiawah Island, SC. *Journal of Pediatric Pharmacy Practice* September/October 1998. Oct. 1998

**Hovinga CA\***, Shinn B. Student vs. Preceptor Assessments During Fourth-Year Clinical Experiences, Poster presentation at the ASHP MidYear Clinical Meeting, New Orleans, LA.. *AJHP* December 1996 Dec. 1996

## **Local Committee Memberships**

---

### **The University of Texas at Austin**

College of Pharmacy

Member, Scientific Review Committee 2020-present.

Member, Curriculum Committee Interprofessional Education (IPE) Subcommittee 2015-2019

Member, Research Infrastructure and Lab Safety Committee 2015-2019

### **Ascension Texas**

Chair, Clinical Trials 2017-2018

Chair, Compliance Committee 2016-2018

Member, Legal Committee 2016-2018

Member, Finance Compliance Committee 2016-2018

### **Seton Family Hospitals**

Hospitals Research Operations Committee 2014-2018

Research Training and Education Committee 2014-2018



<b>Dell Children's Medical Center</b>	
Research Planning Committee	2012-2018
<b>Seton Medical System</b>	
Institutional Review Board Member	2012-2015
IT Infrastructure and Review Committee	2012-2018
<b>University of Tennessee Health Science Center</b>	
Clinical Research Center	
Member, Mentorship Committee	2009-2011
College of Pharmacy	
Member, Postdoctoral Association Committee	2007-2008
Member, Education Credentialing Committee	2007-2008
Member, Research Committee	2006
<b>Cleveland Clinic Foundation-Case Western Reserve</b>	
Member, Medical School Curriculum Committee	2002-2003
<b>Cleveland Clinic Foundation</b>	
Member, Neurology Intensive Care Steering Committee	2001-2003
Member, Pharmacy Department, Poison Prevention Committee	2001
<b>University of Tennessee</b>	
Member, Residency and Fellowship Review Committee	1999-2000
<b>Creighton University School of Pharmacy and Allied Health Professions</b>	
American Pharmacists Association Academy	
Member, Drug Information Committee	1993-1994
<b>Creighton University School of Arts and Sciences</b>	
Member, Biology Department, Curriculum Committee	1990-1991
<b>Miami Children's Hospital</b>	
Animal Research Committee/IACUC Committee	2004-2006
<b>Cleveland Clinic Foundation</b>	
Neurology Clinical Center for Research Task Force	2001-2003

## EDUCATIONAL ACTIVITIES

---

### Post Graduate Education

#### Seton Healthcare Family, Austin TX

Craniofacial Fellowship Course	2014-2018	
Pharmacy Residency Course	2014-2018	
Research Methods and Human Subjects Protection	Oct. 2013-2018	1 CH

#### Seton Healthcare Family, Austin TX

Research Methods and Human Subjects Protection	Oct. 2011, 2012	2 CH
--	-----------------	------

#### University of Texas Southwestern Medical School

Anticonvulsants and Psychiatry	Feb. 2013-2015	1 CH
Psychology Residency Program, Austin TX		
Management of Seizure Disorders	Oct. 2012, 2013	3 CH
Neurology Residency Program, Austin, TX		

#### Miami Children's Hospital, Miami, FL

Clinical Trial Design in Neurosciences	Nov. 2004, Sept. 2005	2 CH
Basic Neuropharmacology: Fellowship Course	Nov. 2004, Sept. 2005	2 CH

#### Cleveland Clinic Foundation, Cleveland, OH

Clinical Trial Design and Regulatory Issues, Laboratory	2001, 2002, 2003	2 CH
Neuropharmacology Lecture and Case Series	2001, 2002, 2003	6 CH
Neuropharmacology Weekly Teaching Rounds	Jan. 2001-2003	

#### Creighton University School of Pharmacy and Allied Health Professions

Functional Anatomy Web-based Instruction, Laboratory	2001, 2002, 2003	4 CH
General Physiology Web-based Instruction, Laboratory	Spring 2001	4 CH

### Clinical Experiential Rotations

#### University of Texas at Austin, College of Pharmacy, Austin, TX

Pediatrics, Clerkship preceptor	2013-2021	
---------------------------------	-----------	--

#### University of Tennessee, College of Pharmacy, Memphis, TN

Pediatric Neurology Pharmacokinetics/Neurology. Clerkship, preceptor	1997-2011	
Pharmacokinetics/Neurology. Clerkship, co-preceptor	1997-2011	
Parental Nutrition. Clerkship, co-preceptor	1997-2011	

## Graduate Lectures

### University of Texas at Austin, Dell Medical School

DMS 2020 Foundations in Interprofessional Collaborative Practice - Faculty Facilitator 2016-present 1 CH

### University of Texas at Austin, College of Pharmacy

Drug Development 2020-present 2 CH  
PHM282 Clinical Perspectives

#### Special Populations

PHM12SP/396D Clinical Pearls in Pediatrics 2012-2020 1 CH

PHM12SP/396D Special Dosing and Administration in Pediatrics 2012-2020 1 CH

PHM12SP/396D Fluid Replacement in Pediatrics 2012-2020 1 CH

PHM12SP/396D Pharmacokinetics and Pharmacodynamics in Pediatrics 2012-2020 1 CH

PHM12F Professional Development Convocation. Recitation/Lab 2012-2020 1 CH

Therapeutics III 2012-present 3 CH

11F/695F Epilepsy, Pharmacotherapeutics III, Lecture

### DeBusk College of Osteopathic Medicine, Lincoln Memorial University, Harrogate, TN

Psychostimulant and ADD/ADHD Pharmacology, Neuroscience, Lecture 2007 1 CH

Antiepileptic Pharmacology, Neuroscience, Lecture 2007 2 CH

### University of Tennessee, College of Pharmacy, Memphis, TN

Pediatrics Selective, Lecture, Case Discussion Brain Development and Neural Tube Defects / Pediatric Epilepsy-Pharmacotherapy 2008, 2009 2 CH

Therapeutics I. Ischemic and Hemorrhagic Stroke Lecture. 2008, 2009 3 CH

Neonatal Selective, Lecture, Case Discussion. Brain Development and Common Neurological Disorders / Neonatal Seizures 2007, 2008 2 CH

Neurology Selective, Lecture-Course Director. 2007 2 CH

Special Problems in Pharmacy, Pediatric Neurology Research, Projects Course 2006-2010 2 CH

Attention Deficit Hyperactivity Disorder. Applied Therapeutics V Lecture 2006-2010 4 CH

Autism. Applied Therapeutics V Lecture 2006-2010 4 CH

Introduction to Pharmacy and the Healthcare Environment, Recitation. 2006-2009 2 CH

Anticonvulsants, Applied Pharmacokinetics Lecture, Recitation. 1999, 2006 2 CH

Phenytoin. Applied Pharmacokinetics. Lecture 1998 2 CH

The Common Cold and Fever. Pediatric Selective Lecture 1998 1 CH

Diaper Rash, Thrush, and Fever. Pediatric Selective Lecture 1998 1 CH

Febrile Seizures. Pediatric Selective Lecture 1998-2000 1 CH

Antipyretics. Over-the Counter Medications Lecture 1998-2000 2 CH

Attention Deficit Hyperactivity Disorder. Pediatric Selective Lecture 1999-2000 2 CH

Congenital Heart Disease. Applied Therapeutics I Lecture	1998-1999	2 CH
Pediatrics. Therapeutics I Lecture/Clerkship	1997	2 CH
Epilepsy. Introduction to Therapeutics, Lecture	1997	1 CH

### **Undergraduate Courses**

#### **Creighton University, School of Arts and Science, Omaha, NE**

Introductory Biology Laboratory, Lecture I	1991, 1992	1 CH
Introductory Biology Laboratory, Lecture II	1991, 1992	1 CH

### **ADVISING AND MENTORING**

---

#### **Graduate Education Research Mentorship**

Kimberly Lewis, RN, MSN, PhD(c) –“ Factors Influencing Hyperlipidemia in Children with Juvenile Arthritis” The University of Texas at Austin, School of Nursing	2014-2016
Komal Gupte, PhD(c) – “The Cost of Refractory Epilepsy in Adults in Texas” The University of Texas at Austin, College of Pharmacy	2014
Brittany Wittenberg, PhD – “Special Needs Assessment and Plan (SNAP) Intervention in Children with Sensory Integration Disorder” The University of Texas at Austin, School of Human Ecology	2013-2016

#### **Residents**

Pharmacy Practice in Psychopharmacology and Medicine-Health Outcomes Research, The University of Texas Austin, College of Pharmacy	
Michelle Blair, PharmD.	2013

#### **Doctor of Pharmacy**

Pediatric Residency, Le Bonheur Children’s Medical Center, Memphis, TN	
Bess Flynn, PharmD.	2008-2009
Cynthia Hanson, PharmD.	2008-2009
Pratish Patel, PharmD.	2008-2009
Kerri Parks, PharmD.	2008-2009
Jessica Robinson, PharmD.	2008-2009
Megan Foster, PharmD.	2007-2008
Becky McGee, PharmD.	2007-2008
David Shoop, PharmD.	2007-2008
Emma Tillman, PharmD.	2007-2008
David Donald, PharmD.	2006-2007
Kelly Earhart, PharmD.	2006-2007
Curtis Petty, PharmD.	2006-2007
Jasmine Sahni, PharmD.	2006-2007
Chastity Sheldon, PharmD	2006-2007

#### **Doctor of Medicine**

Neuropharmacology-Neurology Fellow Cleveland Clinic, Cleveland, OH	
Tobias Loddenkemper, M.D.	2002-2003
Nadine Chehab PharmD.	2002-2003

Andreea Popas, PharmD.	2002-2003
Cornelia Drees, M.D.	2001-2002
Ajay Gupta, M.D.	2001-2002
Rhonda Rhea, PharmD.	2001-2002
Adria Serje, M.D.	2001-2002
David Lazdizabal, M.D.	2000-2003

**EXTERNAL EDUCATIONAL ACTIVITIES: LOCAL GRAND ROUNDS/CONTINUING EDUCATION**

---

<b>Central Texas Epilepsy Foundation, Austin, TX</b> Cannabinoids in the Treatment of Epilepsy.	Jan. 14, 2015
<b>Annual Central Texas Dental Symposium, Austin, TX</b> Top Pediatric Medications.	Apr. 19, 2013
<b>Dell Children’s Medical Center Epilepsy Symposium, Austin, TX</b> Mechanisms of Action of Anticonvulsants From Bromides to Lacosamide.	May 7, 2012
<b>Seton Hospital, Austin, TX.</b> Neuropsychopharmacology and Epilepsy Anticonvulsant Teaching Course	Nov. 8, 2012 Oct. 7-10, 2012
<b>MidSouth Epilepsy Support Foundation, Memphis, TN</b> First and Second Generation Antiepileptic Drugs. Investigational Antiepileptic Medications: Introducing Them Into Practice.	Jun. 9, 2009 Feb. 10, 2009
<b>Office of Clinical Pharmacology, FDA, Silver Springs, MD</b> Translational Research in Neonatal Seizures.	Jun. 8, 2009
<b>Middle and Western Tennessee Epilepsy Foundation, Annual Conference, Jackson, TN</b> Medication Matters In Epilepsy.	Feb. 21, 2009
<b>Dell Children’s Medical Center Grand Rounds, Austin, TX</b> Neonatal Seizures	Mar. 17, 2009
<b>Le Bonheur Children’s Medical Center Grand Rounds, Memphis, TN</b> Pharmacology of Pediatric Epilepsy	Oct. 17, 2007
<b>Ortho McNeil Pharmaceuticals, Miami, FL</b> Pharmacokinetics of Anticonvulsants.	Jun. 4, 2004
<b>Northeast Ohio Consultant Pharmacists, Elyria, OH</b> Epilepsy in the Elderly.	Aug. 22, 2003
<b>Elan Educational Conference. Cleveland, OH</b> Practical Use of Zonegran.	Mar. 13, 2003
<b>Cleveland Clinic Foundation Headache Staff Conference, Cleveland, OH</b> Migraine Pharmacology.	Nov. 12, 2002

<b>Pediatric Epilepsy Case Conference</b> Bioactivation and Idiosyncratic Drug Reactions.	Nov. 6, 2002
<b>GlaxoSmithKline CNS Preceptorship, Cleveland, OH</b> Pharmacology of Headache and Migraine.	Oct. 31, 2002
<b>Cleveland Clinic Foundation</b> Epilepsy Grand Rounds: Drug Interactions and Epilepsy.	Oct. 25, 2002
Neurology Grand Rounds: Antiepileptogenic Drugs in Epilepsy.	Sept. 23, 2002
Epilepsy Postgraduate Course: Practical Guide to the New Anticonvulsants.	Sept. 9, 2002
Epilepsy Postgraduate Course: Pharmacology of the Traditional Anticonvulsants.	Sept. 8, 2002
Epilepsy Postgraduate Course: Research Design and Methods.	Sept. 6, 2002
Neurology Research Conference: Pharmacokinetics of Anticonvulsants in Neonates.	Jun. 7, 2002
Pediatric Neurology Grand Rounds: Overview of New Legislation Affecting Pediatric Drug Research (Is The Rule Dead?).	Jan. 14, 2002
Pharmacy Grand Rounds: Idiopathic Side Effects of the Newer Anticonvulsants: Relevance to Pediatric Patients.	Jan. 9, 2002
Pediatric Neurology Grand Rounds: Update on Lamotrigine Induced Rash: Time to Weigh the Evidence.	Jan. 7, 2002
Pediatric Grand Rounds: Bioactivation and Hypersensitivity Reactions in Epilepsy Across the Lifespan.	Nov. 5, 2002
Grand Rounds: Developmental Pharmacokinetic Pharmacokinetics Across the Lifespan.	Nov. 5, 2002
Pediatric Neurology-Epilepsy Teaching Conference: Monotherapy Trial Design in Refractory Epileptic Patients.	Oct. 21, 2001
Pediatric Noon Conference: Neuropharmacology 101 in Pediatric Patients: Part I.	Oct. 29, 2001
Review of The Monotherapy Trial Design Considerations in Epilepsy. OrthoMcNeil Pharmaceuticals. Cleveland Clinic Foundation, Cleveland, OH,	Sept. 27, 2001
Pediatric Neurology-Epilepsy Teaching Conference: Antiepileptic Pharmacology in the PICU: Part II.	Jun. 27, 2001
Pharmacotherapy Update, Lecture Series. Antiepileptic Medications.	Jun. 25, 2001
Pharmacotherapy Update, Lecture Series. Antiepileptic Medications.	Jun. 11, 2001
Pediatric Neurology-Epilepsy Teaching Conference: Antiepileptic Pharmacology in the PICU: Part I.	Jun. 6, 2001
Neuropharmacology Rounds: New Antiepileptic Medications	Apr. 25, 2001
Divisions of Pharmacy and Nursing Health Odyssey 2001: Through A Looking Glass: "New Antiepileptic Medications: A Practical Approach."	Apr. 23, 2001
Pediatric Neurology-Epilepsy Teaching Conference: Pharmacological Treatment of Nonconvulsive Status Epilepticus.	Mar. 16, 2001
Neuroprotective Properties of the Newer Antiepileptic Medications.	Feb. 23, 2001
Pharmacological Treatment of Nonconvulsive Status Epilepticus	Dec. 14, 2000
PICU Staff: Antiepileptic Pharmacology in the PICU.	Nov. 16, 2000

Use of Intravenous Valproate in Generalized Convulsive Status Epilepticus.	Feb. 10 & 24, 2000
<b>OrthoMcNeil Pharmaceuticals CNS Preceptorship.</b> Anticonvulsant Mechanisms and Therapeutic Uses.	Sept. 26, 2002
<b>GlaxoSmithKline Preceptorship, Cleveland, OH</b> Migraine Pharmacotherapy: Making Sense of All the Choices.	Nov. 5, 2002
<b>Abbott Pharmaceuticals. Cleveland, OH</b> Clinical and Basic Considerations in Neuropharmacology.	Dec. 14, 2001
<b>Elan Pharmaceuticals, Cleveland, OH</b> A Mechanistic Approach to Drug Interactions.	Nov. 17, 2001
<b>University of Connecticut School of Pharmacy</b> Use of Intravenous Valproate in Generalized Convulsive Status Epilepticus.	Jan. 10, 2000
<b>University of Colorado Health Science Center</b> Use of Intravenous Valproate in Generalized Convulsive Status Epilepticus.	Jan. 14, 2000
<b>University of Tennessee School of Pharmacy</b> Use of Intravenous Valproate in Generalized Convulsive Status Epilepticus.	Jan. 17, 2000
<b>University of Tennessee and Tennessee Pharmacists Association</b> 1999 Basic Pharmacology and Therapeutics: Common Pediatric Diseases.	Oct. 15, 1999
1999 Basic Pharmacology and Therapeutics: Attention Deficit Hyperactivity Disorder.	Oct. 15, 1999